Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections
- 24 April 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (7), 953-964
- https://doi.org/10.1517/14656566.7.7.953
Abstract
Colonisation of the gastrointestinal tract by anaerobic bacteria, protozoa, trematodes, cestodes and/or nematodes and other infectious pathogens, including viruses, represents a major cause of morbidity and mortality in Africa, South America and southeast Asia, as well as other parts of the world. Nitazoxanide is a member of the thiazolide class of drugs with a documented broad spectrum of activity against parasites and anaerobic bacteria. Moreover, the drug has recently been reported to have a profound activity against hepatitis C virus infection. In addition, nitazoxanide exhibits anti-inflammatory properties, which have prompted clinical investigations for its use in Crohn's disease. Studies with nitazoxanide derivatives have determined that there must be significantly different mechanisms of action acting on intracellular versus extracellular pathogens. An impressive number of clinical studies have shown that the drug has an excellent bioavailability in the gastrointestinal tract, is fast acting and highly effective against gastrointestinal bacteria, protozoa and helminthes. A recent Phase II study has demonstrated viral response (hepatitis C) to monotherapy, with a low toxicity and an excellent safety profile over 24 weeks of treatment. Pre-clinical studies have indicated that there is a potential for application of this drug against other diseases, not primarily affecting the liver or the gastrointestinal tractKeywords
This publication has 50 references indexed in Scilit:
- Inhibitory Activities of Epidermal Growth Factor Receptor Tyrosine Kinase-Targeted Dihydroxyisoflavone and Trihydroxydeoxybenzoin Derivatives on Sarcocystis neurona , Neospora caninum , and Cryptosporidium parvum DevelopmentAntimicrobial Agents and Chemotherapy, 2005
- Infectivity of Cryptosporidium hominis and Cryptosporidium parvum Genotype 2 Isolates in Immunosuppressed Mongolian GerbilsInfection and Immunity, 2005
- Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspectiveCurrent Medical Research and Opinion, 2005
- The plasma membrane of microaerophilic protists: oxidative and nitrosative stressMicrobiology, 2004
- Nitazoxanide in Treatment of Helicobacterpylori : a Clinical and In VitroStudyAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Parasiticidal Effect of Nitazoxanide against Echinococcus multilocularis MetacestodesAntimicrobial Agents and Chemotherapy, 2003
- Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d.International journal of clinical pharmacology and therapeutics, 2002
- Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from PeruTransactions of the Royal Society of Tropical Medicine and Hygiene, 2002
- Nitazoxanide, a Nitrothiazolide Antiparasitic Drug, Is an Anti-Helicobacter pylori Agent with Anti-Vacuolating Toxin ActivityChemotherapy, 1999
- A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in aids patients in MexicoTransactions of the Royal Society of Tropical Medicine and Hygiene, 1998